Browse > Article

Analysis and Cut-off Adjustment of Dried Blood Spot 17alpha-hydroxyprogesterone Concentration by Birth Weight  

Park, Seungman (Green Cross Laboratories)
Kwon, Aerin (Green Cross Laboratories)
Yang, Songhyeon (Green Cross Laboratories)
Park, Euna (Green Cross Laboratories)
Choi, Jaehwang (Green Cross Laboratories)
Hwang, Mijung (Green Cross Laboratories)
Nam, Hyeongyeong (Green Cross Laboratories)
Lee, Eunhee (Green Cross Laboratories)
Publication Information
Journal of The Korean Society of Inherited Metabolic disease / v.14, no.2, 2014 , pp. 150-155 More about this Journal
Abstract
The measurement of $17{\alpha}$-hydroxyprogesterone ($17{\alpha}$-OHP) in a dried blood spot on filter paper is an important for screening of congenital adrenal hyperplasia (CAH). Since high levels of $17{\alpha}$-OHP are frequently observed in premature infants without congenital adrenal hyperplasia, we evaluated cuts-off based on birth weight and performed validation. Birth weight and $17{\alpha}$-OHP concentration data of 292,204 newborn screening subjects in Greencross labopratories were analyzed. The cut-off values based on birth weight were newly evaluated and validated with the original data. The mean $17{\alpha}$-OHP concentration were 7.25 ng/mL in very low birth weight (VLBW) group, 4.02 ng/mL in low birth weight (LBW) group, 2.53 g/mL in normal birth weight (NBW) group, and 2.24 ng/mL in heavy birth weight (HBW) group. The cut-offs for CAH were decided as follows: 21.12 ng/mL for VLBW and LBW groups and 11.14 ng/mL for NBW and HBW groups. When applied new cut-offs for original data, positive rates in VLBW and LBW groups were decreased and positive rates in NBW and HBW groups were increased. The cut-offs based on birth weight should be used in the screening for CAH. We believe that our new cut-off reduce the false positive rate and false negative rate and our experience for cut-off set up and validation will be helpful for other laboratories doing newborn screening test.
Keywords
Newborn screening; $17{\alpha}$-hydroxyprogesterone ($17{\alpha}$-OHP); Cut-off;
Citations & Related Records
연도 인용수 순위
  • Reference
1 White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245-91.
2 Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003;349:776-88.   DOI   ScienceOn
3 Miller WL, Levine LS. Molecular and clinical advances in congenital adrenal hyperplasia. J Pediatr 1987;111:1-17.   DOI
4 Klingensmith GJ, Garcia SC, Jones HW, Migeon CJ, Blizzard RM. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 1977;90:996-1004.   DOI
5 Migeon CJ. Comments about the need for prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1990;70:836-7.   DOI
6 Pescovitz OH, Comite F, Cassorla F, Dwyer AJ, Poth MA, Sperling MA, et al. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. J Clin Endocrinol Metab 1984;58:857-61.   DOI
7 Mulaikal RM, Migeon CJ, Rock JA. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1987; 316: 178-82.   DOI   ScienceOn
8 Nordenstrom A, Wedell A, Hagenfeldt L, Marcus C, Larsson A. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics 2001;108:E68.   DOI   ScienceOn
9 Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 1997;130:128-33.   DOI   ScienceOn
10 Kang MS, Nahm CH, Choi JW, Jeon YH, Im MW, Lee CH, Pai SH. Analysis of Blood Spot 17-Hydroxyprogesterone Concentration According to Gestational Age and Birth Weight. Korean J Clin Pathol 2001;21:104-8.
11 Oh KI, Kim SJ, Kim DH, Kim JK, Jun YH, Choi JW, Lee JE. Revaluation of Neonatal Screening Test for Congenital Adrenal Hyperplasia. J Korean Soc Pediatr Endocrinol 2006;11:192-8.
12 Ohkubo S, Shimozawa K, Matsumoto M, Kitagawa T. Analysis of blood spot 17 alpha-hydroxyprogesterone concentration in premature infants-proposal for cut-off limits in screening for congenital adrenal hyperplasia. Acta Paediatr Jpn 1992;34:126-33.   DOI   ScienceOn
13 Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogestereone levels. J Pediatr 1997;130:128-33.   DOI   ScienceOn